398,130 Shares in Insulet Corporation $PODD Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp acquired a new stake in shares of Insulet Corporation (NASDAQ:PODD) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 398,130 shares of the medical instruments supplier’s stock, valued at approximately $60,615,000.

Several other institutional investors have also modified their holdings of PODD. Larson Financial Group LLC increased its holdings in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Insulet in the 4th quarter valued at about $26,000. DV Equities LLC purchased a new stake in shares of Insulet in the 4th quarter worth approximately $28,000. Elyxium Wealth LLC purchased a new stake in shares of Insulet in the 4th quarter worth approximately $28,000. Finally, Mcguire Capital Advisors Inc. bought a new position in shares of Insulet during the fourth quarter valued at approximately $29,000.

Analysts Set New Price Targets

PODD has been the topic of several research reports. Oppenheimer lowered shares of Insulet from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Stifel Nicolaus lowered their price target on shares of Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Raymond James Financial reiterated an “outperform” rating and set a $180.00 price objective on shares of Insulet in a research note on Thursday, August 6th. Royal Bank Of Canada decreased their price objective on Insulet from $245.00 to $160.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Finally, Citigroup increased their price objective on shares of Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Fourteen research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $195.40.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s second-quarter results exceeded expectations, with adjusted EPS of $1.66 versus the $1.47 consensus and revenue of $801.7 million versus estimates of $787.4 million. Revenue increased 23.5% year over year, although investors remain focused on whether the company can sustain growth after its 2026 guidance reset. Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
• Neutral Sentiment: Insulet is scheduled to participate in the Wells Fargo 21st Annual Healthcare Conference, giving management an opportunity to address Omnipod demand, retention trends, manufacturing quality and its revised outlook. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: Kestra Medical Technologies appointed Curtis Kopf, Insulet’s former global customer-experience executive, to a senior vice president role. The move is not an operating announcement from Insulet, but could draw attention to executive talent movement and customer-support capabilities in the diabetes-device market. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Multiple law firms are publicizing a federal securities class action against Insulet and certain officers, with an August 31 lead-plaintiff deadline. The complaints allege that the company made misleading statements or failed to disclose material information concerning manufacturing controls, product safety and compliance. The lawsuits are allegations, not established findings, but they increase legal, reputational and potential regulatory risks. Faruqi & Faruqi Insulet Securities Class Action Notice
• Negative Sentiment: Investor notices link the lawsuit to two voluntary Omnipod recalls or medical-device corrections affecting approximately 7 million Pods. Analysts reportedly questioned the scope of Insulet’s manufacturing and quality-control problems, cut valuation assumptions and reduced estimates despite management reiterating guidance. These issues threaten investor confidence in the company’s manufacturing story and could lead to additional scrutiny or costs. PODD Shareholder Alert from Levi & Korsinsky

Insulet Stock Up 0.2%

NASDAQ:PODD opened at $143.38 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The company’s fifty day moving average price is $154.52 and its 200-day moving average price is $182.09. Insulet Corporation has a 1-year low of $126.40 and a 1-year high of $354.88. The firm has a market capitalization of $9.94 billion, a P/E ratio of 26.80, a PEG ratio of 1.13 and a beta of 1.10.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. During the same period in the previous year, the firm posted $1.17 earnings per share. The firm’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, equities research analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.

Insider Activity at Insulet

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.36% of the stock is owned by insiders.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.